Keio University

Tokyo Institute of Technology

Kumamoto University

Fujita Academy

Adiposeeds, Inc.

Sun Pharma Japan Limited

Link Genomis, Inc.

Hideyuki Saya

Osamu Nagano

Yoshimi Arima

Naoki Yamada

Nobuhiro Nishiyama

Yasuo Ikeda

Hiroyasu Takemoto

Takahiro Nomoto

Makoto Matsui

Keishiro Tomoda

Yumiko Matsubara

Shinichiro Niwa

Keiichi Tozawa

Shogo Okazaki

Hidetaka Katabuchi

Ritsuo Honda

Yasutaka Makino

Naoyoshi Koike

Kenji Tsuchihashi

Hiroyuki Nobusue

Oltea Sampetrean

Akiyoshi Kasuga

Nobuo Kubota

Kentaro Suina

Tsukasa Nishimori

Takashi Semba

Provided is an epithelial tissue stem cell derived from an adult, which lacks at least one tumor suppressor gene.

Cell and utilization thereof

A method for producing a mesenchymal cell line derived from a vertebrate adipose tissue, and a mesenchymal cell line derived from a vertebrate adipose tissue produced by the method. Advantageously, a method for producing a mesenchymal cell line derived from a vertebrate adipose tissue is achieved more simply, in a shorter period of time, and more efficiently. Also, a mesenchymal cell line is derived from a vertebrate adipose tissue produced by the production method. The method for producing a mesenchymal cell line derived from a vertebrate adipose tissue comprises: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell of a vertebrate adipose tissue into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate adipose tissue.

Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue

The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.

Cancer stem cell inhibitor

The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.

Antitumor agent

The present invention is directed to provide cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species. To this end, provided are cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species in a cancer stem cell each containing pimozide or sertindole as an active ingredient.

Cancer stem cell proliferation inhibitor and intracellular active oxygen accumulation inducer

Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof.

Prophylactic and/or therapeutic agent for dysmenorrhea

Growing community of inventors

Tokyo, Japan

Hideyuki Saya